Stephen Fitzgerald

Dr. Stephen Fitzgerald


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SWSarah E. Williams-Macdonald
Sarah E. Williams-Macdonald
MMMairi Christine Mitchell
Mairi Christine Mitchell
DFDavid Frew
David Frew
JPJavier Palarea-Albaladejo
Javier Palarea-Albaladejo
DEDavid Ewing
David Ewing
TMTom N McNeilly
Tom N McNeilly
The bacterium Coxiella burnetii can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of C. burnetii to humans; however, the only existing livestock vaccine, namely, Coxevac® (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I C. burnetii strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac® and an experimental bacterin vaccine based on phase II C. burnetii against C. burnetii challenge. Prior to mating, ewes (n = 20 per group) were vaccinated subcutaneously with either Coxevac®, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes (n = 6) from each group was then challenged 151 days later (~100 days of gestation) with 106 infectious mouse doses of C. burnetii, Nine-Mile strain RSA493. Both vaccines provided protection against C. burnetii challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac® can protect ewes against C. burnetii infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.

2 September 2023 in Animals
Verified
Journal Article
Open access
PDF file
SFStephen Fitzgerald
Stephen Fitzgerald
MMMairi Christine Mitchell
Mairi Christine Mitchell
AHAnne Holmes
Anne Holmes
LALesley Allison
Lesley Allison
MCMargo Chase-Topping
Margo Chase-Topping
TMTom N McNeilly
Tom N McNeilly
Shiga toxin-producing E. coli (STEC) infections associated with wildlife are increasing globally, highlighting many ‘spillover’ species as important reservoirs for these zoonotic pathogens. A human outbreak of STEC serogroup O157 in 2015 in Scotland, associated with the consumption of venison meat products, highlighted several knowledge gaps, including the prevalence of STEC O157 in Scottish wild deer and the potential risk to humans from wild deer isolates. In this study, we undertook a nationwide survey of wild deer in Scotland and determined that the prevalence of STEC O157 in wild deer is low 0.28% (95% confidence interval = 0.06–0.80). Despite the low prevalence of STEC O157 in Scottish wild deer, identified isolates were present in deer faeces at high levels (>104 colony forming units/g faeces) and had high human pathogenic potential based on whole genome sequencing and virulence gene profiling. A retrospective epidemiological investigation also identified one wild deer isolate from this study as a possible source of a Scottish human outbreak in 2017. These results emphasise the importance of food hygiene practices during the processing of wild deer carcasses for human consumption.

20 April 2026 in Microbial Genomics
Verified
Journal Article
Open access
ACAntonia Chalka
Antonia Chalka
LCLouise Crozier
Louise Crozier
AVAdriana Vallejo-Trujillo
Adriana Vallejo-Trujillo
ALAlison Low
Alison Low
SMSean McAteer
Sean McAteer
DGDavid L. Gally
David L. Gally
Random forest-based source attribution models were developed from a ‘One Health’ resource comprising 4,230 high-quality whole-genome assemblies from Escherichia coli . These were isolated from a wide range of sources, predominantly originating in Scotland, including wastewater, livestock, food and clinical infections of humans and dogs. Using these models, we derived a probabilistic assignment of E. coli isolates from food, shellfish and water samples to potential livestock and human sources of contamination. The incorporation of E. coli sequences from wastewater alongside those from human clinical infections enabled us to capture a wide diversity of human strains in our analyses. The sequence types (STs) of isolates from human bacteraemia and urinary tract infection (UTI) were compared with livestock and food isolates. While only 2.3% of the E. coli isolated from food samples in the study were from STs primarily associated with human bacteraemia and UTI, the models found a livestock signal associated with 15% of the human clinical isolates. In the food and private water samples, livestock-human co-attribution of E. coli isolates was common and consistent with routine human exposure to specific subsets of livestock E. coli , potentially a result of selection during food and water processing. Overall, this research demonstrates the potential value of including source attribution models in national surveillance programmes to understand the transmission of E. coli through the agri-food chain and support risk management to protect public health.